Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

321. Aspirin resistance.

Aspirin resistance. Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A2 and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance may correlate independently with increasing risk of cardiovascular events. Aspirin resistance can be detected by laboratory tests of platelet thromboxane A2 production or platelet function that depend on platelet thromboxane production. Potential causes of aspirin resistance include inadequate (...) dose, drug interactions, genetic polymorphisms of COX-1 and other genes involved in thromboxane biosynthesis, upregulation of non-platelet sources of thromboxane biosynthesis, and increased platelet turnover. Aspirin resistance can be overcome by treating the cause or causes, and reduced by minimising thromboxane production and activity, and blocking other pathways of platelet activation. Future research is aimed at defining aspirin resistance, developing reliable tests for it, and establishing

Lancet2006

322. Clopidogrel plus aspirin or aspirin alone in unstable angina

Clopidogrel plus aspirin or aspirin alone in unstable angina BestBets: Clopidogrel plus aspirin or aspirin alone in unstable angina Clopidogrel plus aspirin or aspirin alone in unstable angina Report By: Shweta Gidwani - Clinical Effectiveness Fellow Search checked by Richard Body - Clinical Research Fellow Institution: Manchester Royal Infirmary Original author: Shweta Gidwani Original institution: Manchester Royal Infirmary Date Submitted: 25th November 2005 Date Completed: 2nd February 2006 (...) with oxygen, aspirin, nitrates, beta-blockers and heparin, after which he becomes pain free. You also give him clopidogrel 300 mg because you have heard that patients with unstable angina and non ST-elevation MI have a better cardiovascular outcome when treated with a combination of clopidogrel and aspirin versus aspirin alone. You wonder whether there is any evidence to support this. Search Strategy Medline 1966�11/2005 using the OVID interface Embase 1980�2005 week 47 The Cochrane Library Issue 4 2005

BestBETS2006

323. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis

Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Larsson S C, Giovannucci E, Bergkvist L, Wolk A CRD summary The authors concluded that current evidence does not support a link between aspirin and non-steroidal anti-inflammatory drug use and risk (...) of pancreatic cancer. The limited search, absence of a formal validity assessment and limited details about the included studies make it difficult to assess the reliability of the authors’ conclusions. Authors' objectives To investigate the relationship between use of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, and risk of pancreatic cancer. Searching MEDLINE was searched from 1966 to October 2006 for articles in any language; the search terms were reported. The reference lists

DARE.2006

324. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Andreotti F, Testa L, Biondi-Zoccai G G, Crea F CRD summary The review (...) investigated the effect of aspirin combined with warfarin in patients recovering from acute coronary syndromes. The review concluded that at an international normalised ratio of 2-3 the combination of aspirin and warfarin is superior to aspirin alone in reducing the risk of major adverse events, although it significantly increases the risk of major bleeding. The conclusion appears reliable. Authors' objectives To determine the effect of aspirin plus warfarin (A+W) compared with aspirin alone

DARE.2006

325. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Berger J S, Roncaglioni M C, Avanzini F, Pangrazzi I, Tognoni G, Brown D L CRD (...) summary This review concluded that aspirin reduces the risk of stroke in women and of myocardial infarction in men, but increases the risk of major bleeding for both groups. The conclusion appears to follow from evidence presented, although the search for studies could have been more extensive and the inadequate description of the review methods makes it difficult to verify the findings. Authors' objectives To determine the effect of aspirin in the primary prevention of cardiovascular disease in women

DARE.2006

326. Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation

Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Annemans L, Lamotte M, Kubin M, Evers T, Verheugt F W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of low-dose aspirin (75 to 325 mg) in the primary prevention of cardiovascular disease (CVD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients aged

NHS Economic Evaluation Database.2006

327. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Pignone M, Earnshaw S, Tice J A, Pletcher M J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of aspirin, statins, and a combination of aspirin and statins for the primary prevention of coronary heart disease (CHD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

NHS Economic Evaluation Database.2006

328. Aspirin

Aspirin Aspirin ASP Drugs October 2006 Page 1 of 1 Drugs PRESENTATION 300 milligram aspirin (acetylsalicylic acid) in tablet form (dispersible). ACTIONS Has an anti-platelet action which reduces clot formation. Analgesic, anti-pyretic and anti-in?ammatory. CAUTIONS As the likely bene?ts of a single 300 milligram aspirin outweigh the potential risks, aspirin may be given to patients with: Asthma Pregnancy Kidney or liver failure Gastric or duodenal ulcer SIDE EFFECTS Gastric bleeding. Wheezing (...) in some asthmatics. DOSAGE AND ADMINISTRATION Adults Adults with apparent, suspected or possible myocardial infarction. Route: Oral – chewed or dissolved in water INDICATIONS Adults with: clinical or ECG evidence of myocardial infarction or ischaemia central chest pain, possibly of cardiac origin. Aspirin should be administered to any patient with chest pain unless the diagnosis is very clearly non- cardiac or the drug is contraindicated. CONTRA-INDICATIONS Known aspirin allergy or sensitivity

Joint Royal Colleges Ambulance Liaison Committee2006

329. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Article Text Therapeutics Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death

Evidence-Based Medicine (Requires free registration)2006

330. Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Article Text Therapeutics Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Statistics from

Evidence-Based Medicine (Requires free registration)2006

331. Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia

Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia Article Text Therapeutics Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after

Evidence-Based Medicine (Requires free registration)2006

332. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. 16531616 2006 04 20 2006 04 26 2016 08 03 1533-4406 354 16 2006 Apr 20 The New England journal of medicine N. Engl. J. Med. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. 1706-17 Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. We randomly assigned (...) 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes. The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin

NEJM2006

333. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. 16765759 2006 06 12 2006 06 22 2016 11 24 1474-547X 367 9526 2006 Jun 10 Lancet (London, England) Lancet Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE (...) W): a randomised controlled trial. 1903-12 Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events. Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated

Lancet2006

334. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. 16714187 2006 05 22 2006 06 08 2015 06 16 1474-547X 367 9523 2006 May 20 Lancet (London, England) Lancet Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. 1665-73 Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events (...) after ischaemic stroke of presumed arterial origin are inconsistent. Our aim was to resolve this uncertainty. We did a randomised controlled trial in which we assigned patients to aspirin (30-325 mg daily) with (n=1363) or without (n=1376) dipyridamole (200 mg twice daily) within 6 months of a transient ischaemic attack or minor stroke of presumed arterial origin. Our primary outcome event was the composite of death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction

Lancet2006

335. Aspirin and the risk of intracranial complications following head injury

Aspirin and the risk of intracranial complications following head injury BestBets: Aspirin and the risk of intracranial complications following head injury Aspirin and the risk of intracranial complications following head injury Report By: Magdy Sakr - Consultant in Emergency Medicine Search checked by Libby Wilson - Clinical Research Fellow Institution: University Hospitals of Coventry and Warwickshire Date Submitted: 12th November 2003 Date Completed: 24th November 2005 Last Modified: 12th (...) November 2003 Status: Green (complete) Three Part Question In [adults with head injury] does [pre-injury aspirin] adversely [affect clinical outcome]? Clinical Scenario A 65 year old man on aspirin presents to the emergency department having fallen sustaining a minor head injury. You wonder whether he is at higher risk of intracranial bleeding due to aspirin. Search Strategy Medline using the OVID interface 1966- August Week 4 2005 Embase 1980�2005 week 37 The Cochrane Library Issue 3 2005 Medline

BestBETS2005

336. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. CONTEXT: Randomized trials of short-term aspirin use for prevention of recurrent colorectal adenoma have provided compelling evidence of a causal relationship between aspirin and colorectal neoplasia. However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited. OBJECTIVE (...) : To examine the influence of aspirin and NSAIDs in prevention of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 82 911 women enrolled in the Nurses' Health Study providing data on medication use biennially since 1980 and followed up through June 1, 2000. MAIN OUTCOME MEASURE: Incident colorectal cancer. RESULTS: Over a 20-year period, we documented 962 cases of colorectal cancer. Among women who regularly used aspirin (> or =2 standard [325-mg] tablets per week

JAMA2005 Full Text: Link to full Text with Trip Pro

337. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.

Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. OBJECTIVE: To investigate the routine use of low dose aspirin in people aged > or = 70 without overt cardiovascular disease. DESIGN: Epidemiological modelling in a hypothetical population. SETTING: Reference populations of men and women in the year 2000 from the state of Victoria, Australia. SUBJECTS: 10,000 men and 10,000 women aged 70-74 (...) with no cardiovascular disease. MAIN OUTCOME MEASURES: First ever myocardial infarction or unstable angina, ischaemic or haemorrhagic stroke, and major gastrointestinal haemorrhage. Health adjusted years of life lived. RESULTS: The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women

BMJ2005 Full Text: Link to full Text with Trip Pro

338. Aspirin in the treatment of acute pulmonary embolism

Aspirin in the treatment of acute pulmonary embolism BestBets: Aspirin in the treatment of acute pulmonary embolism Aspirin in the treatment of acute pulmonary embolism Report By: Caroline Lee - Senior Clinical Fellow Search checked by Craig Ferguson - Clinical Research Fellow Institution: Manchester Royal Infirmary Date Submitted: 2nd November 2004 Date Completed: 18th May 2005 Last Modified: 18th May 2005 Status: Green (complete) Three Part Question In [a patient with suspected acute (...) pulmonary embolus] is [aspirin] effective in [reducing morbidity and mortality]? Clinical Scenario A 50 year old woman presents to the emergency department with shortness of breath and pleurtic chest pain, following a flight from Australia. Examination is unremarkable except for tachypnoea and mild hypoxia. CXR is also normal, so you aim to treat for suspected pulmonary embolus. You know that aspirin is used in the treatment of other acute thromboembolic conditions eg CVA or MI, and in the prophylaxis

BestBETS2005

339. Narrative review: aspirin resistance and its clinical implications.

Narrative review: aspirin resistance and its clinical implications. Aspirin is currently the most cost-effective drug for the secondary prevention of cardiovascular disease, but treatment failures are relatively common. Several factors have been linked to these recurrent vascular events in patients prescribed aspirin, including smoking, drug interactions, nonadherence, comorbid conditions, and aspirin resistance. The term aspirin resistance has been used to describe not only an absence (...) of the expected pharmacologic effects of aspirin on platelets but also poor clinical outcomes, such as recurrent vascular events, in patients treated with aspirin. Aspirin resistance is perhaps more precisely understood as the phenomenon of measurable, persisting platelet activation that occurs in patients prescribed a therapeutic dose of aspirin and may underlie an unknown proportion of aspirin treatment failures. Key challenges for future research are to standardize a definition of aspirin resistance

Annals of Internal Medicine2005

340. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. BACKGROUND: Although clopidogrel plus aspirin is more effective than aspirin alone in preventing subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combination has yet to be examined in this high-risk population. OBJECTIVE: To determine the cost-effectiveness of clopidogrel plus aspirin compared (...) with aspirin alone. DESIGN: Cost-utility analysis. DATA SOURCES: Published literature. TARGET POPULATION: Patients with unstable angina and electrocardiographic changes or non-Q-wave myocardial infarction. time horizon: Lifetime. PERSPECTIVE: Societal. INTERVENTIONS: Combination therapy with clopidogrel, 75 mg/d, plus aspirin, 325 mg/d, for 1 year, followed by aspirin monotherapy, was compared with lifelong aspirin therapy, 325 mg/d. OUTCOME MEASURES: Lifetime costs, life expectancy in quality-adjusted

Annals of Internal Medicine2005